Summary of changes from the previous recommendations from the fourth IWWM, published in 2009
| Clinical condition . | New recommendation (2014) . | Old recommendation (2009) . |
|---|---|---|
| Cytopenias | DRC, bendamustine-rutuximab, bortezomib-rituximab | DRC, thalidomide + rituximab |
| High M-protein, transplant candidate | Bendamustine-rutuximab, bortezomib-rituximab | R-CHOP, DRC |
| High M-protein, non-transplant candidate | Bendamustine-rutuximab, bortezomib-rituximab | Nucleoside analogs + rituximab; nucleoside analogs + rituximab + cyclophosphamide |
| Comorbidities and cytopenias | Rituximab | Rituximab |
| Older age, slow progression, candidate for oral therapy | Oral fludarabine | Cladribine |
| Clinical condition . | New recommendation (2014) . | Old recommendation (2009) . |
|---|---|---|
| Cytopenias | DRC, bendamustine-rutuximab, bortezomib-rituximab | DRC, thalidomide + rituximab |
| High M-protein, transplant candidate | Bendamustine-rutuximab, bortezomib-rituximab | R-CHOP, DRC |
| High M-protein, non-transplant candidate | Bendamustine-rutuximab, bortezomib-rituximab | Nucleoside analogs + rituximab; nucleoside analogs + rituximab + cyclophosphamide |
| Comorbidities and cytopenias | Rituximab | Rituximab |
| Older age, slow progression, candidate for oral therapy | Oral fludarabine | Cladribine |